AMENDMENT 4 TO SUB-LICENCE AND COLLABORATION AGREEMENTSub-Licence and Collaboration Agreement • August 7th, 2019 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances)
This Fourth Amendment (the “Amendment”) to the Sub-Licence and Collaboration Agreement dated 20 March 2012, as amended (the “2012 Agreement”) is entered into and effective as of the last date of signature (the “Amendment Effective Date”), by and between:
AMENDMENT NO. 3 TO SUB-LICENCE AND COLLABORATION AGREEMENTSub-Licence and Collaboration Agreement • August 7th, 2019 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances)
This Amendment No. 3 to Sub-Licence and Collaboration Agreement (“Amendment No.3”) is effective as of 31 December 2015 (the “Amendment No.3 Effective Date”) by and between MedImmune, LLC, a Delaware limited liability company with a place of business at One MedImmune Way, Gaithersburg, MD20878, United States (“MedImmune”) and Humabs BioMed SA, a limited company organized under the laws of Switzerland having its head office at Via Mirasloe 1, Bellinzona CH-6500, Switzerland ( “Humabs”). MedImmune and Humabs are each referred to herein as a “Party” and collectively as the “Parties”.
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. September 7, 2018 Eric Victory Vice President & Head...Sub-Licence and Collaboration Agreement • August 7th, 2019 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances)
As you know, Humabs Biomed SA (“Humabs”), a wholly owned subsidiary of Vir Biotechnology Inc., and MedImmune, LLC (“MedImmune”) are parties to that certain Sub-Licence and Collaboration Agreement dated March 20, 2012, as amended (the “Agreement”). By this letter amendment (this “Amendment”), Humabs and MedImmune agree to amend the Agreement as described below, effective as of the date first set forth above.
